Abstract: A composition comprising an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C), for the use in the treatment of a cognitive or neurological disorder in a patient, said patient having been pre-treated with naltrexone, or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine.

Abstract: A composition comprising an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 3, for the use in the treatment of a cognitive or neurological disorder in a patient, said patient having been pre-treated with naltrexone, or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine.

Abstract: A pharmaceutical composition comprising naltrexone or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, for use in the treatment of an autoimmune disease within a subject, wherein a therapeutically effective amount of the naltrexone or metabolite thereof or analogue of either is to be administered to the subject in a first treatment phase, wherein after the first treatment phase the subject is to be administered a therapeutically effective amount of a cannabinoid, flavonoid or terpene in a second treatment phase, and wherein an agonist of a 5-hydroxytryptamine (5-HT) receptor is to be administered to the subject either simultaneously, sequentially or separately with the naltrexone, the metabolite or analogue.

Abstract: The invention is a single unit oral dose pharmaceutical composition comprising a first active ingredient and a second active ingredient; wherein the first active ingredient is for absorption in the gastrointestinal tract from the oesophagus onwards; wherein the second active ingredient is for absorption in the oral cavity; and wherein the first active ingredient is naltrexone in an amount of 0.01 to 10 mg and the second active ingredient is calcitriol in an amount of 80 to 200 ug. The pharmaceutical composition is particularly effective in the treatment of cancer.

Abstract: The invention relates to a precast monument base which is made from precast concrete, and is capable of being installed during any kind of weather conditions. The idea basically involves the utilization of a resilient layer between the base and the base cap to allow proper leveling, and to prevent the entrance of moisture to create problems under freezing conditions. The base extends below the frost line, and hence is not effected by freezing of the ground or excessive amounts of water or moisture.